Mineralys Therapeutics Analyst Ratings
Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Cuts Target Price to $29
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $26 to $45
Buy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat Trials
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)
Mineralys Therapeutics Analyst Ratings
Buy Rating Justified by Mineralys Therapeutics' Promising Hypertension and CKD Drug Lorundrostat
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Mineralys Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)
Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Mineralys Therapeutics, Inc. (MLYS)
Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $37
Mineralys Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Eli Lilly & Co (LLY)
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy From Credit Suisse
Credit Suisse Reiterates Outperform on Mineralys Therapeutics, Maintains $38 Price Target
Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Cara Therapeutics (CARA) and Mineralys Therapeutics, Inc. (MLYS)
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $38 From $40, Keeps Outperform Rating
No Data